Global Peptic Ulcer Drugs Market 2017-2021

  • ID: 4328331
  • Report
  • Region: Global
  • 84 pages
  • TechNavio
OFF
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 5

FEATURED COMPANIES

  • AstraZeneca
  • Daewoong Pharmaceuticals
  • Eisai
  • MORE
About Peptic Ulcer Drugs

A peptic ulcer is an open lesion, which develops on the mucosal lining of the stomach and the small intestine due to the caustic effect of the gastric acid and pepsin present in these organs. The general symptoms of a peptic ulcer include abdominal pain, nausea, vomiting, and bloated stomach. The specific symptom of peptic ulcer is the bleeding of the ulcer, which can be life-threatening. It is detected by bloody and sticky stools, often black in color. It is caused mainly by the Helicobacter pylori bacteria followed by the overuse of over-the-counter (OTC) non-steroidal anti-inflammatory drugs (NSAIDs) like naproxen, aspirin, and ibuprofen.

The analysts forecast the global peptic ulcer drugs market to grow at a CAGR of 2.80% during the period 2017-2021.

Covered in this report

The report covers the present scenario and the growth prospects of the global peptic ulcer drugs market for 2017-2021. To calculate the market size, the report considers the sales of branded, generic, and off-label drugs.

The market is divided into the following segments based on geography:
  • Americas
  • APAC
  • EMEA
The report, Global Peptic Ulcer Drugs Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors
  • AstraZeneca,
  • Daewoong Pharmaceuticals,
  • Eisai,
  • Takeda Pharmaceutical
Other prominent vendors
  • GlaxoSmithKline
  • Pfizer
Market drivers
  • Economics of treating ulcer
  • For a full, detailed list, view the full report
Market challenges
  • Adverse effect of PPIs
  • For a full, detailed list, view the full report
Market trends
  • Bismuth-based quadruple therapy
  • For a full, detailed list, view the full report
Key questions answered in this report
  • What will the market size be in 2021 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?
You can request one free hour of the analyst’s time when you purchase this market report. Details are provided within the report.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • AstraZeneca
  • Daewoong Pharmaceuticals
  • Eisai
  • MORE
PART 01: Executive summary

PART 02: Scope of the report

PART 03: Research Methodology

PART 04: Introduction
  • Market outline
PART 05: Peptic ulcers: Disease overview

PART 06: Key clinical trials

PART 07: Market landscape
  • Market overview
  • Market size and forecast
  • Five forces analysis
PART 08: Market segmentation by drug class
  • PPIs
  • Antibiotics
  • Others
PART 09: Geographical segmentation
  • Peptic ulcer drugs market in Americas
  • Peptic ulcer drugs market in EMEA
  • Peptic ulcer drugs market in APAC
PART 10: Decision framework

PART 11: Drivers and challenges
  • Market drivers
  • Market challenges
PART 12: Market trends
  • Bismuth-based quadruple therapy
  • Emergence of monotherapy
  • Recurrent H. pylori infections
  • Rise in awareness
PART 13: Vendor landscape
  • Competitive scenario
PART 14: Key vendor analysis
  • AstraZeneca
  • Daewoong Pharmaceuticals
  • Eisai
  • Takeda Pharmaceutical
  • Other prominent vendors
PART 15: Appendix
  • List of abbreviations
List of Exhibits
Exhibit 01: Types of peptic ulcer
Exhibit 02: Global peptic ulcer drugs market: Pipeline landscape based on sponsors
Exhibit 03: Global peptic ulcer drugs market: Pipeline landscape
Exhibit 04: Global peptic ulcer drugs market: List of clinical trials and their aim/purpose
Exhibit 05: Snapshot of global peptic ulcer drugs market
Exhibit 06: Global peptic ulcer drugs market 2016-2021 ($ millions)
Exhibit 07: Opportunity analysis in global peptic ulcer drugs market
Exhibit 08: Five forces analysis
Exhibit 09: Segmentation of global peptic ulcer drugs market based on drug class 2016
Exhibit 10: Global peptic ulcer drugs market share based on drug class 2016
Exhibit 11: Global peptic ulcer PPIs drugs market 2016-2021 ($ millions)
Exhibit 12: Global peptic ulcer antibiotics drugs market 2016-2021 ($ millions)
Exhibit 13: Global peptic ulcer drugs market for others 2016-2021 ($ millions)
Exhibit 14: Segmentation of global peptic ulcer drugs market based on geography 2016 and 2021
Exhibit 15: Segmentation of global peptic ulcer drugs market revenue based on geography 2016-2021
Exhibit 16: Segmentation of global peptic ulcer drugs market based on geography 2016-2021 (%)
Exhibit 17: Market scenario in Americas
Exhibit 18: Peptic ulcer drugs market in Americas 2016-2021 ($ millions)
Exhibit 19: Market scenario in EMEA
Exhibit 20: Peptic ulcer drugs market in EMEA 2016-2021 ($ millions)
Exhibit 21: Market scenario in APAC
Exhibit 22: Peptic ulcer drugs market in APAC 2016-2021 ($ millions)
Exhibit 23: Age-related proportion of patients with duodenal and gastric ulcer
Exhibit 24: Some of the marketed combination products
Exhibit 25: Revenue erosion of Pariet after loss of exclusivity
Exhibit 26: Competitive structure analysis of global peptic ulcer drugs market 2016
Exhibit 27: AstraZeneca: Key highlights
Exhibit 28: AstraZeneca: Strength assessment
Exhibit 29: AstraZeneca: Strategy assessment
Exhibit 30: AstraZeneca: Opportunity assessment
Exhibit 31: Daewoong Pharmaceuticals: Key highlights
Exhibit 32: Daewoong Pharmaceuticals: Strength assessment
Exhibit 33: Daewoong Pharmaceuticals: Strategy assessment
Exhibit 34: Daewoong Pharmaceuticals: Opportunity assessment
Exhibit 35: Eisai: Key highlights
Exhibit 36: Eisai: Strength assessment
Exhibit 37: Eisai: Strategy assessment
Exhibit 38: Eisai: Opportunity assessment
Exhibit 39: Takeda Pharmaceutical: Key highlights
Exhibit 40: Takeda Pharmaceutical: Strength assessment
Exhibit 41: Takeda Pharmaceutical: Strategy assessment
Exhibit 42: Takeda Pharmaceutical: Opportunity assessment
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5

FEATURED COMPANIES

  • AstraZeneca
  • Daewoong Pharmaceuticals
  • Eisai
  • MORE
New Report Released: - Global Peptic Ulcer Drugs Market 2017-2021

The author of the report recognizes the following companies as the key players in the global peptic ulcer drugs market: AstraZeneca, Daewoong Pharmaceuticals, Eisai, and Takeda Pharmaceutical.

Other Prominent Vendors in the market are: GlaxoSmithKline and Pfizer.

Commenting on the report, an analyst from the research team said: “The latest trend gaining momentum in the market is Bismuth-based quadruple therapy. Bismuth-based quadruple therapy has emerged as an alternative therapy to address the demand for anti-resistant drugs for the treatment of peptic ulcer. The traditional treatment regimen for peptic ulcer involves the use of clarithromycin or levofloxacin-based triple therapy, which became resistant to H. pylori bacteria, thus leaving most individuals untreated. To offset the impact of antibiotic resistance, the modern therapeutic approach for the treatment of peptic ulcer is based on bismuth-based quadruple therapy, which involves the use of drugs, such as bismuth salt, tetracycline, and metronidazole, for which antibiotic resistance is rarely encountered.”

According to the report, one of the major drivers for this market is economics of treating ulcer. The under use of antibiotic therapy for the treatment of peptic ulcer associated with H. pylori infection not only leads to unnecessary loss of productivity but also causes enormous economic loss to the individual. As per a CDC report, approximately 10%-15% of peptic ulcer adults living in the US are in poor health condition and unable to perform routine activities.

Further, the report states that one of the major factors hindering the growth of this market is Adverse effect of PPIs. As per the US FDA, the use of PPIs for acid suppression in peptic ulcer patients is associated with an increased risk of CDAD. C. difficile is a bacterium, which causes diarrhea that does not improve over time. Its symptoms include watery stools, abdominal pain, fever, and may even lead to severe intestinal conditions. CDAD causes loss of vital nutrients from the body, and its treatment involves administration of fluids rich in nutrients and electrolyte in combination with antibiotics. The US FDA recommends CDAD diagnosis for patients with diarrhea that does not improve over time.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Note: Product cover images may vary from those shown
5 of 5
  • AstraZeneca
  • Daewoong Pharmaceuticals
  • Eisai
  • Takeda Pharmaceutical.GlaxoSmithKline and Pfizer
Note: Product cover images may vary from those shown
6 of 5
Note: Product cover images may vary from those shown
Adroll
adroll